Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19568597 | 1.00 | ATF4 (0.56) | ATF4SMN1; SMN2NPC1PKMEPHX2 | |
| SCHEMBL23149159 | 0.85 | ATF4 (0.71) | ATF4NPC1RAB9ALMNAMEN1 | |
| SCHEMBL22627657 | 0.85 | ATF4 (0.56) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL20609274 | 0.84 | ATF4 (0.76) | ATF4 | |
| SCHEMBL19577632 | 0.84 | ATF4 (0.54) | ATF4SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL22990649 | 0.84 | ATF4 (0.54) | ATF4SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL22990531 | 0.84 | ATF4 (0.54) | ATF4SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL19577718 | 0.84 | ATF4 (0.54) | ATF4SMN1; SMN2RAB9AALDH1A1LMNA | |
| SCHEMBL20610423 | 0.81 | ATF4 (0.80) | ATF4NPC1RAB9A | |
| SCHEMBL23624503 | 0.81 | ATF4 (0.51) | ATF4SMN1; SMN2RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345727-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885SMN1; SMN2 2486/4885NPC1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.